NovalGen

Clinical-stage biotechnology company advancing breakthrough multi-specific biologics to transform outcomes in oncology, autoimmune, haematological, and metabolic disorders.

Pharmacist using her digital tablet while working in a aisle

NovalGen is a clinical-stage biotechnology company advancing breakthrough multi-specific biologics to transform outcomes in oncology, autoimmune, haematological, and metabolic disorders. 

Their dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated bispecific antibody products tailored to the needs of the patient, enabling life-enhancing treatments for people with haematologic and solid tumours. 

The company’s lead program, NVG-222, is an ROR1-targeting bispecific antibody T-cell engager using their breakthrough bispecific and Autoregulation technology targeting liquid and solid tumors.

The NovalGen journey so far:

  • 2019: spinout founded 
  • 2026: Cancer Research UK and NovalGen dose the first patient in the Phase 1 trial of T-cell engager NVG-222
Dr Rick Fagan

Dr. Rick Fagan

Director of BioPharm

Dr Fagan is a cell and molecular biologist by training, gaining his PhD at McGill University, Canada. This was followed by a postdoctorate at the Imperial Cancer Research Fund, London, and then the National Institute for Medical Research.

Richard left to join AstraZeneca as a team leader in the Department of Target Discovery, then worked for SanofiAventis as a senior team leader. In 2001 he left SanofiAventis and joined Impharmatica as Associate Director Target Discovery and worked very closely with the business development team.

In 2006 he joined UCL Ventures as Assistant Director BioPharm, becoming Director in 2007.